Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Genscript Biotech

SEHK:1548
Snowflake Description

Reasonable growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1548
SEHK
HK$22B
Market Cap
  1. Home
  2. HK
  3. Pharmaceuticals & Biotech
Company description

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. The last earnings update was 2 days ago. More info.


Add to Portfolio Compare Print
  • Genscript Biotech has significant price volatility in the past 3 months.
1548 Share Price and Events
7 Day Returns
-0.2%
SEHK:1548
2.1%
HK Life Sciences
4%
HK Market
1 Year Returns
-20%
SEHK:1548
19.1%
HK Life Sciences
-20.3%
HK Market
1548 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genscript Biotech (1548) -0.2% -26.9% -34% -20% 182.4% -
HK Life Sciences 2.1% -15.8% -6.5% 19.1% 106.2% 70.5%
HK Market 4% -11.9% -15.8% -20.3% -13% -22.3%
1 Year Return vs Industry and Market
  • 1548 underperformed the Life Sciences industry which returned 19.1% over the past year.
  • 1548 matched the Hong Kong Market (-20.3%) over the past year.
Price Volatility
1548
Industry
5yr Volatility vs Market

Value

 Is Genscript Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Genscript Biotech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Genscript Biotech.

SEHK:1548 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year HK Government Bond Rate 1.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SEHK:1548
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year HK Govt Bond Rate 1.6%
Equity Risk Premium S&P Global 6.3%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.029 (1 + (1- 25%) (0.84%))
1.024
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.02
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.55% + (1.024 * 6.33%)
8.03%

Discounted Cash Flow Calculation for SEHK:1548 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Genscript Biotech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SEHK:1548 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.03%)
2020 -60.40 Analyst x1 -55.91
2021 101.30 Analyst x1 86.80
2022 84.33 Est @ -16.75% 66.89
2023 74.84 Est @ -11.26% 54.95
2024 69.29 Est @ -7.42% 47.09
2025 66.02 Est @ -4.73% 41.53
2026 64.14 Est @ -2.84% 37.35
2027 63.16 Est @ -1.53% 34.05
2028 62.78 Est @ -0.6% 31.33
2029 62.81 Est @ 0.04% 29.01
Present value of next 10 years cash flows $373.00
SEHK:1548 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $62.81 × (1 + 1.55%) ÷ (8.03% – 1.55%)
$984.15
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $984.15 ÷ (1 + 8.03%)10
$454.56
SEHK:1548 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $373.00 + $454.56
$827.56
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $827.56 / 1,882.34
$0.44
SEHK:1548 Discount to Share Price
Calculation Result
Exchange Rate USD/HKD
(Reporting currency to currency of SEHK:1548)
7.752
Value per Share
(HKD)
= Value per Share in USD x Exchange Rate (USD/HKD)
= $0.44 x 7.752
HK$3.41
Value per share (HKD) From above. HK$3.41
Current discount Discount to share price of HK$11.86
= -1 x (HK$11.86 - HK$3.41) / HK$3.41
-248%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Genscript Biotech is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genscript Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genscript Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SEHK:1548 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.05
SEHK:1548 Share Price ** SEHK (2020-03-27) in HKD HK$11.86
SEHK:1548 Share Price converted to USD reporting currency Exchange rate (HKD/ USD) 0.129 $1.53
Hong Kong Life Sciences Industry PE Ratio Median Figure of 6 Publicly-Listed Life Sciences Companies 45.07x
Hong Kong Market PE Ratio Median Figure of 1,494 Publicly-Listed Companies 8.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genscript Biotech.

SEHK:1548 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:1548 Share Price ÷ EPS (both in USD)

= 1.53 ÷ -0.05

-29.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genscript Biotech is loss making, we can't compare its value to the HK Life Sciences industry average.
  • Genscript Biotech is loss making, we can't compare the value of its earnings to the Hong Kong market.
Price based on expected Growth
Does Genscript Biotech's expected growth come at a high price?
Raw Data
SEHK:1548 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -29.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
122.9%per year
Asia Life Sciences Industry PEG Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 1.46x
Hong Kong Market PEG Ratio Median Figure of 480 Publicly-Listed Companies 0.63x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genscript Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genscript Biotech's assets?
Raw Data
SEHK:1548 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.21
SEHK:1548 Share Price * SEHK (2020-03-27) in HKD HK$11.86
SEHK:1548 Share Price converted to USD reporting currency Exchange rate (HKD/ USD) 0.129 $1.53
Hong Kong Life Sciences Industry PB Ratio Median Figure of 7 Publicly-Listed Life Sciences Companies 4.81x
Hong Kong Market PB Ratio Median Figure of 2,250 Publicly-Listed Companies 0.71x
SEHK:1548 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:1548 Share Price ÷ Book Value per Share (both in USD)

= 1.53 ÷ 0.21

7.44x

* Primary Listing of Genscript Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genscript Biotech is overvalued based on assets compared to the HK Life Sciences industry average.
X
Value checks
We assess Genscript Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Genscript Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Genscript Biotech expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
122.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genscript Biotech expected to grow at an attractive rate?
  • Genscript Biotech's earnings growth is expected to exceed the low risk savings rate of 1.6%.
Growth vs Market Checks
  • Genscript Biotech's earnings growth is expected to exceed the Hong Kong market average.
  • Genscript Biotech's revenue growth is expected to exceed the Hong Kong market average.
Annual Growth Rates Comparison
Raw Data
SEHK:1548 Future Growth Rates Data Sources
Data Point Source Value (per year)
SEHK:1548 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 122.9%
SEHK:1548 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 17.3%
Asia Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 29.4%
Asia Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 22.2%
Hong Kong Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Hong Kong Market Revenue Growth Rate Market Cap Weighted Average 9.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SEHK:1548 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SEHK:1548 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 387 77 2
2020-12-31 324 -38 2
2020-03-29
SEHK:1548 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 273 -18 -97
2019-09-30 257 -116 -59
2019-06-30 241 -214 -22
2019-03-31 236 41 0
2018-12-31 231 295 21
2018-09-30 216 332 24
2018-06-30 201 369 27
2018-03-31 177 195 26
2017-12-31 153 21 26
2017-09-30 139 24 27
2017-06-30 125 27 28
2017-03-31 120 30 27

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genscript Biotech's earnings are expected to grow significantly at over 20% yearly.
  • Genscript Biotech's revenue is expected to grow by 17.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SEHK:1548 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Genscript Biotech Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:1548 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.04 0.04 0.04 1.00
2020-12-31 -0.02 -0.02 -0.02 1.00
2020-03-29
SEHK:1548 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.05
2019-09-30 -0.03
2019-06-30 -0.01
2019-03-31 0.00
2018-12-31 0.01
2018-09-30 0.01
2018-06-30 0.02
2018-03-31 0.02
2017-12-31 0.02
2017-09-30 0.02
2017-06-30 0.02
2017-03-31 0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Genscript Biotech is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Genscript Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genscript Biotech has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Genscript Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genscript Biotech's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genscript Biotech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Genscript Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genscript Biotech's 1-year growth to the HK Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Genscript Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genscript Biotech Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:1548 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 273.35 -96.91 125.61 186.02
2019-09-30 257.01 -59.28 112.24 147.53
2019-06-30 240.67 -21.65 98.86 109.04
2019-03-31 235.85 -0.22 89.11 91.56
2018-12-31 231.02 21.22 79.35 74.08
2018-09-30 216.25 23.94 72.42 57.61
2018-06-30 201.48 26.66 65.49 41.14
2018-03-31 177.07 26.39 56.22 29.60
2017-12-31 152.65 26.12 46.95 18.06
2017-09-30 138.79 27.04 48.13 11.42
2017-06-30 124.92 27.96 49.31 4.78
2017-03-31 119.83 27.06 50.30 2.39
2016-12-31 114.74 26.17 51.30
2016-09-30 106.80 25.56 49.70
2016-06-30 98.86 24.95 48.11
2016-03-31 92.78 21.23 47.14
2015-12-31 86.71 17.50 46.18
2015-09-30 82.12 12.69 42.82
2015-06-30 77.52 7.88 39.46
2015-03-31 73.76 7.03 38.22
2014-12-31 69.99 6.18 36.98
2013-12-31 60.10 6.00 29.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genscript Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Genscript Biotech has efficiently used its assets last year compared to the HK Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genscript Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Genscript Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genscript Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Genscript Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genscript Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genscript Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genscript Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genscript Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 29.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genscript Biotech Company Filings, last reported 2 months ago.

SEHK:1548 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 372.30 18.76 426.52
2019-09-30 372.30 18.76 426.52
2019-06-30 459.00 19.19 504.55
2019-03-31 459.00 19.19 504.55
2018-12-31 493.30 10.50 564.61
2018-09-30 493.30 10.50 564.61
2018-06-30 504.44 0.61 657.54
2018-03-31 504.44 0.61 657.54
2017-12-31 228.32 0.00 126.95
2017-09-30 228.32 0.00 126.95
2017-06-30 203.97 0.00 131.93
2017-03-31 203.97 0.00 131.93
2016-12-31 184.02 0.00 136.46
2016-09-30 184.02 0.00 136.46
2016-06-30 176.61 1.24 122.07
2016-03-31 176.61 1.24 122.07
2015-12-31 149.25 0.00 103.72
2015-09-30 149.25 0.00 103.72
2015-06-30 69.00 0.00 25.68
2015-03-31 69.00 0.00 25.68
2014-12-31 61.75 8.17 28.16
2013-12-31 52.56 7.39 26.56
  • Genscript Biotech's level of debt (5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (13.1% vs 5% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Genscript Biotech's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Genscript Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genscript Biotech has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Genscript Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genscript Biotech dividends.
If you bought HK$2,000 of Genscript Biotech shares you are expected to receive HK$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genscript Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genscript Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SEHK:1548 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Asia Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 0.5%
Hong Kong Market Average Dividend Yield Market Cap Weighted Average of 966 Stocks 4.2%
Hong Kong Minimum Threshold Dividend Yield 10th Percentile 1.4%
Hong Kong Bottom 25% Dividend Yield 25th Percentile 2.6%
Hong Kong Top 25% Dividend Yield 75th Percentile 7.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SEHK:1548 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-03-29
SEHK:1548 Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2018-09-21 0.000 0.000
2018-08-27 0.000 0.000
2018-04-23 0.000 0.000
2017-05-31 0.002 0.146

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genscript Biotech has not reported any payouts.
  • Unable to verify if Genscript Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genscript Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genscript Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genscript Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genscript Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genscript Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Genscript Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Fangliang Zhang
COMPENSATION $320,000
AGE 54
CEO Bio

Dr. Fangliang Zhang serves as the Chairman of Genscript Biotech Corporation. Dr. Zhang is Chief Executive Officer and Co-Founder of Genscript Biotech Corporation and has been its Director since August 24, 2015. He has been Executive Director of Genscript Biotech Corp. since August 24, 2015. He is one of the founders of Genscript Corporation Dr. Zhang has nearly 20 years of experience in the biotechnology industry. Prior to joining Genscript Biotech, from 1995 to 2002, he worked as a postdoctoral research fellow and an associate principal scientist at Schering-Plough. Dr. Zhang worked in the tumor biology department during his postdoctoral research at Schering-Plough. Dr. Zhang was also one of the key team members for an anti-cancer drug, farnesyl transferase inhibitor. After Dr. Zhang postdoctoral studies, he was recruited to the department of central nervous system and cardiovascular system at Schering-Plough. He became one of the project leaders focusing on G-protein coupled receptors and led a group of scientists to discover the drug target for a billion-dollar drug. As a result of this discovery, Dr. Zhang won a Presidential Award at Schering-Plough in 2001. He was involved in a variety of key biotechnological research projects and provided guidance and directions to those biotechnological research projects. Dr. Zhang was also awarded the National Thousand Talents Program Distinguished Expert in 2010 and the Jiangsu Province High-Level Creative Talent Strategic Award in 2011. Dr. Zhang has published more than 15 biotechnology related scientific papers in international peer-reviewed journals and has been the inventor for more than five patents in relation to biotechnological products and/or services. He serves as a director of Genscript Corporation (GS Corp). Dr. Zhang serves as director of Nanjing Jinsirui Biotechnology Co., Ltd., Jinsikang Technology (Nanjing) Co., Ltd., Nanjing Bestzyme Bioengineering Co., Ltd., Hubei Bestzyme Biotechnology Co., Ltd., Shanghai Jingrui Biotechnology Co., Ltd., Bestzyme Biotech Corporation, Bestzyme Biotech Limited, Bestzyme Biotech USA Incorporated, Bestzyme Biotech HK Limited, Nanjing Legend Biotechnology Co., Ltd., Legend Biotech Corporation, Legend Biotech Limited, Legend Biotech HK Limited, Genscript Biotech Limited, GenScript (Hong Kong) Limited, Genscript International Limited and GenScript USA Incorporated. Dr. Zhang obtained a Bachelor of Engineering degree from Chengdu College of Geology (known as Chengdu University of Technology) in the PRC in July 1984 and a Master of Science degree from Nanjing University in the PRC in July 1987. He also obtained a Doctor of Philosophy degree from Duke University in the U.S. in September 1995.

CEO Compensation
  • Fangliang's compensation has increased whilst company is loss making.
  • Fangliang's remuneration is lower than average for companies of similar size in Hong Kong.
Management Team Tenure

Average tenure and age of the Genscript Biotech management team in years:

4.6
Average Tenure
51
Average Age
  • The tenure for the Genscript Biotech management team is about average.
Management Team

Fangliang Zhang

TITLE
Co-Founder
COMPENSATION
$320K
AGE
54

Ye Wang

TITLE
Co-Founder
COMPENSATION
$429K
AGE
50

Jiange Meng

TITLE
Vice President of Investor Relations & Executive Director
COMPENSATION
$196K
AGE
51
TENURE
2.3 yrs

Li Zhu

TITLE
Chief Strategy Officer
AGE
69
TENURE
2.9 yrs

Chuan-Chu Chou

TITLE
Head of Discovery and Preclinical Services
AGE
65
TENURE
7.4 yrs

Chifa Zhang

TITLE
Department Head of Industry Synthetic Biology Product Segment
AGE
44
TENURE
6.2 yrs

Wai Ling Wong

TITLE
Company Secretary
AGE
39
TENURE
4.6 yrs

Yuan Xu

TITLE
Chief Executive Officer of Legend
AGE
51
Board of Directors Tenure

Average tenure and age of the Genscript Biotech board of directors in years:

4.6
Average Tenure
52.5
Average Age
  • The tenure for the Genscript Biotech board of directors is about average.
Board of Directors

Fangliang Zhang

TITLE
Co-Founder
COMPENSATION
$320K
AGE
54

Ye Wang

TITLE
Co-Founder
COMPENSATION
$429K
AGE
50
TENURE
4.8 yrs

Jiange Meng

TITLE
Vice President of Investor Relations & Executive Director
COMPENSATION
$196K
AGE
51
TENURE
4.6 yrs

Hong Xin Guo

TITLE
Independent Non-Executive Director
COMPENSATION
$90K
AGE
55
TENURE
4.6 yrs

Zumian Dai

TITLE
Independent Non-Executive Director
COMPENSATION
$90K
AGE
42
TENURE
4.6 yrs

Luquan Wang

TITLE
Non-Executive Director
AGE
50
TENURE
4.8 yrs

Yuexin Pan

TITLE
Non-Executive Director
COMPENSATION
$90K
AGE
61
TENURE
4.6 yrs

Jon Stonehouse

TITLE
Member of Advisory Board
AGE
58

Jiuan Pan

TITLE
Independent Non-Executive Director
COMPENSATION
$3K
AGE
50
TENURE
1.3 yrs

Jiafen Wang

TITLE
Non-Executive Director
COMPENSATION
$3K
AGE
67
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (HK$) Value (HK$)
19. Dec 19 Sell Jiange Meng Individual 16. Dec 19 16. Dec 19 -204,597 HK$18.74 HK$-3,833,922
16. Apr 19 Sell GenScript Corporation Company 11. Apr 19 11. Apr 19 -878,000 HK$21.59 HK$-18,957,074
16. Apr 19 Sell GenScript Corporation Company 12. Apr 19 12. Apr 19 -4,090,000 HK$21.49 HK$-87,893,272
16. Apr 19 Sell GenScript Corporation Company 15. Apr 19 15. Apr 19 -1,032,000 HK$21.94 HK$-22,638,984
15. Apr 19 Sell GenScript Corporation Company 10. Apr 19 10. Apr 19 -1,035,789 HK$20.25 HK$-20,969,757
X
Management checks
We assess Genscript Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genscript Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Genscript Biotech Corporation's (HKG:1548) 5.9% ROE Worse Than Average?

By way of learning-by-doing, we'll look at ROE to gain a better understanding Genscript Biotech Corporation (HKG:1548). … One way to conceptualize this, is that for each HK$1 of shareholders' equity it has, the company made HK$0.059 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Should You Be Concerned About Genscript Biotech Corporation's (HKG:1548) Earnings Growth?

Assessing Genscript Biotech Corporation's (HKG:1548) performance as a company requires looking at more than just a years' earnings data. … Below, I will run you through a simple sense check to build perspective on how Genscript Biotech is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its life sciences industry peers. … View our latest analysis for Genscript Biotech?

Simply Wall St -

Is Genscript Biotech Corporation's (HKG:1548) PE Ratio A Signal To Sell For Investors?

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market. … and want to better understand how you can grow your money by investing in Genscript Biotech Corporation (HKG:1548). … Genscript Biotech Corporation (HKG:1548) trades with a trailing P/E of 195.7x, which is higher than the industry average of 32.8x.

Simply Wall St -

It's Time To Buy Genscript Biotech Corporation (HKG:1548)

High quality stocks such as Genscript Biotech Corporation has fared well over time in a fickle stock market, which is why I want to bring it into light amongst all the chaos. … Check out our latest analysis for Genscript Biotech. … Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services

Simply Wall St -

Genscript Biotech Corporation (HKG:1548): Poised For Long-Term Success?

The latest earnings announcement Genscript Biotech Corporation's (SEHK:1548) released in December 2017 suggested that the business endured a minor headwind with earnings declining from US$26.17M to US$26.12M, a change of -0.18%. … Below is my commentary, albeit very simple and high-level, on how market analysts predict Genscript Biotech's earnings growth outlook over the next few years and whether the future looks brighter. … This means that, we can expect Genscript Biotech will grow its earnings by 25.01% every year for the next couple of years.

Simply Wall St -

How Did Genscript Biotech Corporation's (HKG:1548) 11.83% ROE Fare Against The Industry?

Since Genscript Biotech’s return covers its cost in excess of 3.06%, its use of equity capital is efficient and likely to be sustainable. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity SEHK:1548 Last Perf Apr 27th 18 Basically, profit margin measures how much of revenue trickles down into earnings which illustrates how efficient the business is with its cost management. … Currently, Genscript Biotech has no debt which means its returns are driven purely by equity capital.

Simply Wall St -

Genscript Biotech Corporation (HKG:1548): All You Need Is Growth?

With zero-debt on its balance sheet, 1548 doesn't have to worry about maintaining a high level of cash to meet debt obligations and paying near-term interest costs. … 1548 has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … At 1.74 billion shares, that's a HK$43.65B market cap - which is too high, even for a company that has a 5-year cumulative average growth rate (CAGR) of 23.18% (source: analyst consensus).

Simply Wall St -

Why Genscript Biotech Corporation's (HKG:1548) Ownership Structure Is Important

With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in 1548 should also look at another important group of investors: private companies, with a stake of 51.06%, who are primarily invested because of strategic and capital gain interests. … Thus, investors should dig deeper into 1548's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: Institutional ownership level and composition in 1548 is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

It's Time To Buy Genscript Biotech Corporation (HKG:1548)

Today I want to bring to light the market's darling - Genscript Biotech Corporation. … View our latest analysis for Genscript Biotech Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services. … Genscript Biotech tick the boxes in terms of its scale, financial health and proven track record, but there are a few other things I have yet to consider.

Simply Wall St -

Should You Sell Genscript Biotech Corporation (HKG:1548) At This PE Ratio?

Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for 1548 Price per share = $2.4 Earnings per share = $0.017 ∴ Price-Earnings Ratio = $2.4 ÷ $0.017 = 145.5x The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. … 1548’s P/E of 145.5x is higher than its industry peers (37.7x), which implies that each dollar of 1548’s earnings is being overvalued by investors. … For example, if you are inadvertently comparing riskier firms with 1548, then 1548’s P/E would naturally be higher than its peers since investors would reward its lower risk with a higher price.

Simply Wall St -

Company Info

Description

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates in four segments: Bio-Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Bio-Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein production, peptide synthesis, and antibody development for use in basic biology studies, disease and pharmaceutical research, drug discovery, agriculture, environmental studies, and food industry; life sciences research catalogue products, such as pre-packaged, ready-to-use, and off-the-shelf products; and contractual research services, including protein engineering. The Biologics Development Services segment provides various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for antibody therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops therapies for the treatment of liquid tumors. Genscript Biotech Corporation has a strategic collaboration agreement with Selecxine Inc. for the development of antibody drugs. The company was founded in 2002 and is headquartered in Nanjing, China. Genscript Biotech Corporation is a subsidiary of GenScript Corporation.

Details
Name: Genscript Biotech Corporation
1548
Exchange: SEHK
Founded: 2002
HK$22,324,587,707
1,882,342,977
Website: http://www.genscript.com
Address: Genscript Biotech Corporation
Jiangning Science Park,
No. 28, Yongxi Road,
Nanjing,
Jiangsu Province, 211122,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 1548 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 30. Dec 2015
OTCPK GNNS.F Ordinary Shares Pink Sheets LLC US USD 30. Dec 2015
DB G51 Ordinary Shares Deutsche Boerse AG DE EUR 30. Dec 2015
SHSC 1548 Ordinary Shares Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect HK HKD 30. Dec 2015
SZSC 1548 Ordinary Shares The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect HK HKD 30. Dec 2015
Number of employees
Current staff
Staff numbers
3,738
Genscript Biotech employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/29 13:34
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.